Which is better, MTD or NNNN?

On the Buffett-Fit framework, Anbio Biotechnology Class A Ordinary Shares (NNNN) currently grades higher than MTD — 58/100 (C grade) vs 69/100 (B). That said, "better" depends on which framework you trust — MTD wins on Warren Buffett, Joel Greenblatt, and Charlie Munger; NNNN wins on Benjamin Graham, Philip Fisher, Peter Lynch, and Terry Smith. The full pillar breakdown is on this page.

Should I buy MTD or NNNN?

This page is an educational comparison, not investment advice. Both MTD and NNNN are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is MTD better than NNNN for value investing?

On the Buffett-style value-investing framework, NNNN currently grades higher — 69/100 vs 58/100, a 11-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between MTD and NNNN on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). MTD currently scores 69/100 (B grade); NNNN scores 58/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, MTD or NNNN?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. MTD and NNNN are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, MTD or NNNN?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are MTD and NNNN both Healthcare stocks?

Yes — both Mettler-Toledo International Inc. (MTD) and Anbio Biotechnology Class A Ordinary Shares (NNNN) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this MTD vs NNNN comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Mettler-Toledo International

Anbio Biotechnology

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

MTD

Market cap

$22.29B

Sector

Healthcare

NNNN

Anbio Biotechnology

Market cap

$1.43B

Sector

Healthcare

Overall winner

Anbio Biotechnology NNNN

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	MTD	NNNN	Winner
Warren Buffett	69B	58C	MTD
Benjamin Graham	65B	87A	NNNN
Philip Fisher	63C	89A	NNNN
Peter Lynch	66B	95A	NNNN
Joel Greenblatt	68B	36D	MTD
Charlie Munger	74B	73C	MTD
Terry Smith	70B	72C	NNNN

Side-by-side metrics

Metric	MTD	NNNN
Market cap	$22.29B	$1.43B
P/E (TTM)	25.3x	171.9x
EV/EBIT	21.6x	212.9x
ROIC (TTM)	36.09%	21.48%
Gross margin	57.79%	87.06%
Net margin	21.4%	73.75%
Revenue CAGR 5y	2.01%	18.21%
EPS CAGR 5y	6.12%	58.42%
Debt / Equity	-	-
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

MTD leads on

Debt / Equity-vs -+100%
Market cap$22.29Bvs $1.43B+94%
EV/EBIT21.6xvs 212.9x+90%
P/E (TTM)25.3xvs 171.9x+85%

NNNN leads on

EPS CAGR 5y58.42%vs 6.12%+90%
Revenue CAGR 5y18.21%vs 2.01%+89%
Net margin73.75%vs 21.4%+71%
Gross margin87.06%vs 57.79%+34%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Mettler-Toledo International

Anbio Biotechnology

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like MTD

More like NNNN

Related on invest-like

Key terms in this analysis